Related Experiment Videos
Treatment of chronic hepatitis C in children
1Dipartimento di Medicina Clinica e Sperimentale, Clinica Medica 5, University of Padova, Italy. fbortol@ux1.unipd.it
Insights
Chronic hepatitis C in children is generally mild but can progress. Interferon treatment shows limited but potentially similar response rates to adults, especially for specific genotypes.
Area of Science:
- Pediatric Gastroenterology
- Hepatology
- Viral Infections
Background:
- Chronic hepatitis C (HCV) in children is typically mild but rarely resolves spontaneously.
- Disease progression, including fibrosis, increases with illness duration.
- Interferon-based therapies are being explored for pediatric HCV.
Purpose of the Study:
- To evaluate the efficacy and safety of interferon treatment in children with chronic hepatitis C.
- To compare treatment outcomes in pediatric patients with adult data.
- To identify factors influencing treatment response in children.
Main Methods:
- Review of available therapeutic trials involving children with chronic hepatitis C.
- Analysis of treatment response rates (end-of-treatment and sustained response).
- Consideration of patient characteristics, including underlying diseases and HCV genotypes.
Main Results:
- Pediatric trials often include limited numbers of patients, frequently with comorbidities.
- Reported sustained response rates in recent pediatric studies appear comparable to adult rates (8-20%).
- HCV genotypes 2 and 3, and low viremia levels may predict better interferon response.
Conclusions:
- Interferon treatment for chronic hepatitis C in children shows modest efficacy.
- Outcomes require cautious interpretation due to limited trial data and patient heterogeneity.
- HCV genotype and viral load are potential indicators for selecting pediatric candidates for interferon therapy.
Abstract:
Chronic hepatitis C is a mild disease in childhood; however, it has a low rate of spontaneous remission over the years and fibrosis seems to increase along with the duration of the illness. Therefore, interferon treatment has been proposed in recent years. Unfortunately, available therapeutic trials include very few children, often with underlying diseases, and the results, sometimes very encouraging, have to be interpreted with caution. Overall, it seems that the rate of end-of-treatment and of sustained response to interferon reported in more recent studies may be similar to that in adults (8-20% for sustained response). HCV genotypes 2 and 3 and low levels of viremia could be factors in the selection of candidates with greater chances of response to interferon.